GPC3/Mesothelin-CAR-γδT Cells Against Cancers

This study tests a new type of immune cell therapy using gamma-delta T cells (a special type of immune cell) engineered to attack cancer cells that carry proteins called GPC3 or Mesothelin. It targets several types of advanced cancers including liver, lung, and pancreatic cancers. **You may be eligible if...** - You have advanced cancer that tests positive for GPC3 or Mesothelin protein - Your life expectancy is more than 12 weeks - Your heart, lungs, liver, kidneys, and blood counts are in adequate condition - Your engineered T cells meet quality requirements (at least 20% CAR expression) - If you have liver cancer, your liver disease severity is manageable (Child-Pugh score less than 7) **You may NOT be eligible if...** - Your cancer does not express GPC3 or Mesothelin - You are too ill to tolerate the treatment - Your T cells do not meet the required quality standards after manufacturing Talk to your doctor to see if this trial is right for you.